Equity Overview
Price & Market Data
Price: $1.89
Daily Change: $0.00 / 0.00%
Daily Range: $1.48 - $2.12
Market Cap: $316,804,992
Daily Volume: 14,974,434
Performance Metrics
1 Week: -3.57%
1 Month: 8.62%
3 Months: -19.57%
6 Months: 44.27%
1 Year: 183.1%
YTD: -19.57%
Company Details
Employees: 14
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.